Media
Corporate Communications
Here you can find a variety of information:
- Press releases and Brief news
- Key dates for journalists
- Pictures, videos, audio files, press kits and other documents
- Social media channels
- Personal contacts
Our Corporate Communications team can be reached at pr-fre@fresenius.com.
“A pharmacy today? We need to expand it or add something new to it.” (Dr. Eduard Fresenius, Founder, 1912)
February 22, 2023 - 10:00 am
Bad Homburg, Germany
Press Conference Full Year Results 2022, Fresenius and Fresenius Medical Care
News
-
Fresenius SE hosts Kabi Capital Markets Day outlining pathway towards sustainable value creation in line with #FutureFresenius
![]()
Fresenius SE hosts Kabi Capital Markets Day outlining pathway towards sustainable value creation in line with #FutureFresenius
Today, Fresenius SE is hosting a Capital Markets Day in London focused on Fresenius Kabi, a global health care company that specializes in essential health care products for critically and chronically ill patients.
May 25, 2023 · Fresenius Kabi
-
Fresenius places sustainable Schuldschein loan of 850 million euros
Fresenius places sustainable Schuldschein loan of 850 million euros
The healthcare group Fresenius has issued its first sustainability-linked Schuldschein loan with a volume of 850 million euros.
May 22, 2023 · Fresenius
-
Brief News
Fresenius Kabi launches first biosimilar in the U.S.
Fresenius Kabi’s Biosimilar Stimufend® (pegfilgrastim-fpgk) is now available from Fresenius Kabi in the United States. Stimufend® was approved by the U.S. Food and Drug Administration (FDA) in September 2022 for use in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. It is Fresenius Kabi’s first U.S. biosimilar launch. The expansion of the company’s global biosimilars portfolio with a focus on oncology and immunology is an important milestone in its Vision 2026 growth strategy. * Stimufend® (pegfilgrastim-fpgk) is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries. Stimufend is a pegfilgrastim biosimilar medicine of Neulasta®, which is a registered trademark of Amgen Inc.
February 16, 2023 · Fresenius Kabi
Contact
Social Media
Dennis Hofmann
Head of Corporate Communications T +49 (0) 6172 608-96008